Lycia Therapeutics, Inc.
South San Francisco, California, United States · Biotechnology
Lycia is a Series B biotech company building upon the novel platform developed by academic founder Professor Carolyn Bertozzi at Stanford University to develop LYTAC (lysosomal targeting chimera) protein degraders that harness the cell’s lysosomal trafficking and degradation pathway to target both soluble and membrane-bound extracellular proteins. Applications of the LYTAC platform include: target
Key facts
- Headquarters
- South San Francisco, California, United States
- Employees
- 37
- Industries
- Biotechnology
- Status
- Public (LYCA)
- Website
- lyciatx.com
- Company page
Recent activity at Lycia Therapeutics, Inc.
- : Lycia Therapeutics
- : Lycia Therapeutics
- : Lycia Therapeutics raised $106M in a Series C financing led by Venrock Healthcare Capital Partners for the development of lysosomal targeting chimeras (lytacs) to treat autoimmune and inflammatory diseases.
- : Lycia Therapeutics, Inc.
- : Lycia Therapeutics, Inc.
Lycia Therapeutics, Inc. funding history
| Date | Round | Amount |
|---|---|---|
| Jun 2026 | Series D | $75.0M |
| May 2024 | Venture | $106.6M |
| May 2024 | Series C | $106.0M |
| Sep 2021 | Venture | $70.1M |
| Mar 2020 | Venture | $25.4M |
Leadership
- Steve Staben, Director
- Aetna Wun Trombley, Executive Officer, Director
- Laurent Fischer, Director
- Thomas Woiwode, Director
- Clare Ozawa, Director
- Jeremy Caldwell, Executive Officer, Director
- Chin Lee, Chief Medical Officer
Verified email and direct lines for Lycia Therapeutics, Inc.’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Lycia Therapeutics, Inc. files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Lycia Therapeutics, Inc. in the news
- Lycia Therapeutics Completes $106.6 Million Series C Financing to Advance Pipeline of LYTAC Extracellular Protein Degraders to the Clinic - Yahoo Finance (May 13, 2024)
- Lycia Therapeutics Announces Pricing of Upsized Initial Public Offering - GlobeNewswire (Oct 22, 2026)
- Lycia Therapeutics Announces the Appointment of Chin Lee, MD, MPH, as Chief Medical Officer and Reveals Immunology Pipeline - BioSpace (Feb 11, 2025)
- Lycia Therapeutics, Inc. (LYCA) stock price, news, quote and history - Yahoo Finance Singapore (Oct 23, 2026)
- Lilly and Lycia Therapeutics Enter into Strategic Collaboration to Discover and Develop Novel Lysosomal Targeting Chimera (LYTAC) Degraders - PR Newswire (Aug 25, 2021)
- Lilly and Lycia Therapeutics Enter into Strategic Collaboration to Discover and Develop Novel Lysosomal Targeting Chimera (LYTAC) Degraders - Eli Lilly (Aug 25, 2021)
- Lycia Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares - GlobeNewswire (Oct 26, 2026)
- Lycia Therapeutics Raises $75 Million in Oversubscribed - GlobeNewswire (Jun 25, 2026)
Companies similar to Lycia Therapeutics, Inc.
- Korsana Biosciences · Biotechnology
- BloomX · Biotechnology
- Morphocell Technologies · Biotechnology
- Pressure Chemical · Biotechnology
- Accuryn Medical · Biotechnology
About Lycia Therapeutics, Inc.: questions and answers
What does Lycia Therapeutics, Inc. do?
Lycia is a Series B biotech company building upon the novel platform developed by academic founder Professor Carolyn Bertozzi at Stanford University to develop LYTAC (lysosomal targeting chimera) protein degraders that harness the cell’s lysosomal trafficking and degradation pathway to target both soluble and membrane-bound extracellular proteins. Applications of the LYTAC platform include: target
Where is Lycia Therapeutics, Inc. headquartered?
Lycia Therapeutics, Inc. is headquartered in South San Francisco, California, United States.
How many employees does Lycia Therapeutics, Inc. have?
Lycia Therapeutics, Inc. has about 37 employees.
Has Lycia Therapeutics, Inc. raised funding?
Yes. Fundz has recorded 5 funding events for Lycia Therapeutics, Inc.. The most recent, Series D of $75.0M, was in Jun 2026.
What is the latest news on Lycia Therapeutics, Inc.?
On Jun 25, 2026, Lycia Therapeutics
Is Lycia Therapeutics, Inc. a public company?
Yes. Lycia Therapeutics, Inc. is publicly traded under the ticker LYCA.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy